Imatinib Mesylate Tablet, Film Coated
Product Images NDC 62135-659

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 62135-659). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Imatinib Mesylate 100mg Bottle Label)

Imatinib Mesylate 100 mg film-coated tablets label. The label shows the product name, strength, dosage form, and a count of 90 tablets. It is marked Rx Only and labeled by Chartwell RX, LLC. Storage instructions and a barcode are also present, along with a note about no varnish on the packaging.*

FDA Label Image

Image Description (Imatinib Mesylate 400mg Bottle Label)

Label for Imatinib Mesylate 400 mg film-coated tablets by Chartwell RX, LLC. The bottle contains 30 tablets for oral use, prescription only. The label includes storage instructions, dosage information, a barcode, and warnings to keep out of reach of children. The label also states 'No Varnish'.*

FDA Label Image

Image Description (Imatinib Mesylate Graph 1)

A Kaplan-Meier survival curve plot comparing the percentage of patients without progression over time (months since randomization) between Imatinib Mesylate Tablets and IFN+Ara-C treatment arms. The graph includes number of patients with progression, censored cases, hazard ratio with 95% confidence interval, and log-rank test p-value indicating statistical significance.*

FDA Label Image

Image Description (Imatinib Mesylate Graph 2)

A Kaplan-Meier survival curve showing the percentage of patients without progression to AP (accelerated phase) or BC (blast crisis) over months since randomization, comparing Imatinib Mesylate Tablets arm and IFN+Ara-C arm. The graph includes numbers of patients at risk, hazard ratio with confidence interval, and p-value from a log-rank test.*

FDA Label Image

Image Description (Imatinib Mesylate Graph 3)

A Kaplan-Meier survival curve labeled 'Figure 3: Study 1 Recurrence-Free Survival (ITT Population)' comparing recurrence-free survival probabilities over time in months for Imatinib 400 mg and placebo groups. The y-axis shows the probability of being alive and recurrence-free, while the x-axis represents survival time in months up to 108 months. Censoring is indicated for both groups, and patient numbers at risk are listed below the graph at various time points.*

FDA Label Image

Image Description (Imatinib Mesylate Graph 4)

A Kaplan-Meier curve showing recurrence-free survival over time in months for two groups treated with Imatinib at 12 months and 36 months. The vertical axis represents the probability of recurrence-free survival, and the horizontal axis shows survival time in months. Symbols indicate censored observations. The graph includes hazard ratio, confidence interval, and P-value data for statistical comparison.*

FDA Label Image

Image Description (Imatinib Mesylate Graph 5)

A Kaplan-Meier survival curve illustrating the overall survival probability over time in months for two groups treated with Imatinib Mesylate (12 months vs. 36 months). The plot includes censored observations and displays the hazard ratio, confidence interval, and p-value for comparison between groups.*

FDA Label Image

Image Description (Imatinib Mesylate Structure)

Chemical structure of Imatinib Mesylate, showing its molecular configuration with multiple rings and functional groups representing the compound used as a human prescription drug in tablet form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.